Egalet Ltd. is a specialty pharma company focusing on pain management. Egalet Ltd. has several opioid compounds in development and the most advanced program (Egalet® morphine) has completed phase II and an end of phase II meeting has been scheduled with the FDA.

Egalet Ltd. holds various proprietary drug delivery technologies within formulation and development that enables it to develop controlled release products with unique plasma profiles, true drug abuse deterrent and no alcohol dose dumping.
The Egalet® tablet is one in a series of controlled release products developed by Egalet Ltd.

The Egalet® technology works by incorporating the active ingredient into a polymeric matrix that is eroded by body fluids at a constant rate. The tablet is made by way of injection moulding techniques involving only a few steps and low production cost.

The Egalet® technique breaks new ground because it can be used for virtually any type of compound and because it provides controlled release with unusual precision and reliability.

The Parvulet® delivery platform is facilitating dispensing of oral doses especially to the pediatric and geriatric patient segments, especially when large doses are required.

Egalet Ltd. is funded by strong international and Scandinavian Venture Funds.